Horizon Therapeutics (NASDAQ:HZNP) had its price target boosted by equities researchers at Cantor Fitzgerald from $32.00 to $36.00 in a note issued to investors on Friday, The Fly reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 22.03% from the stock’s current price.
Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a research report on Tuesday, October 29th. ValuEngine downgraded Horizon Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Piper Jaffray Companies set a $33.00 price objective on Horizon Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 26th. Stifel Nicolaus set a $35.00 price objective on Horizon Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Bank of America assumed coverage on Horizon Therapeutics in a research note on Thursday, September 26th. They issued a “buy” rating and a $34.00 price target for the company. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $33.77.
Shares of NASDAQ:HZNP traded down $0.15 during trading on Friday, reaching $29.50. 1,544,700 shares of the company traded hands, compared to its average volume of 1,697,509. The company’s 50 day moving average is $27.75 and its two-hundred day moving average is $25.95. The firm has a market capitalization of $5.57 billion, a PE ratio of 16.12, a PEG ratio of 1.76 and a beta of 0.83. The company has a quick ratio of 2.12, a current ratio of 2.20 and a debt-to-equity ratio of 0.90. Horizon Therapeutics has a 52 week low of $17.94 and a 52 week high of $31.25.
Horizon Therapeutics (NASDAQ:HZNP) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.14. The firm had revenue of $335.50 million during the quarter, compared to the consensus estimate of $330.60 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The company’s revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.65 EPS. As a group, research analysts anticipate that Horizon Therapeutics will post 1.58 EPS for the current year.
In other news, CEO Timothy P. Walbert sold 320,174 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $28.02, for a total value of $8,971,275.48. Following the transaction, the chief executive officer now owns 892,483 shares in the company, valued at $25,007,373.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian K. Beeler sold 12,475 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $30.02, for a total value of $374,499.50. The disclosure for this sale can be found here. Insiders sold 576,405 shares of company stock worth $16,126,099 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of HZNP. New York State Teachers Retirement System purchased a new stake in shares of Horizon Therapeutics during the second quarter valued at approximately $55,000. Quadrant Capital Group LLC purchased a new stake in shares of Horizon Therapeutics during the third quarter valued at approximately $66,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Horizon Therapeutics during the second quarter valued at approximately $76,000. FNY Investment Advisers LLC purchased a new stake in shares of Horizon Therapeutics during the second quarter valued at approximately $80,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Horizon Therapeutics by 384.1% during the second quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,689 shares during the last quarter. 86.70% of the stock is owned by institutional investors.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: What is a stock split?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.